Shots:

• The companies collaborated to research, develop, and commercialize novel monospecific antibody candidates with innovative therapeutic options for cancer patients & will continue to share costs and profits on a 50:50 basis
• The collaboration will use Genmab’s HexaBody technology platform to develop novel monospecific Abs & expand BioNTech’s Ab portfolio and strengthen its oncology pipeline to address unmet medical needs for cancer patients
• The clinical trial for GEN1053/BNT313 is expected to be initiated at the end of 2022. GEN1046/BNT311 (DuoBody-PD-L1x4-1BB) is being studied in P-I/II clinical trials for advanced solid tumors, P-II study for NSCLC

Ref: GlobeNewswire | Image: Genmab